by TractManager | Jun 2, 2022 | Health Technology Assessment
Focus of the Report: This Health Technology Assessment focuses on the use of functional electrical stimulation (FES) for treatment of foot drop in patients who have a history of stroke an average of ≥ 1 year prior to FES treatment. This mean 1-year threshold was...
by TractManager | Jun 2, 2022 | Emerging Technology Report
Quell is a wearable transcutaneous electrical nerve stimulator (TENS) device indicated as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity, including use during sleep. If you have a Hayes login, click here to view the full report...
by TractManager | Jun 2, 2022 | News
The U.S. Food and Drug Administration (FDA) announced on June 1, 2022, that Ukoniq (umbralisib; TG Therapeutics Inc.) is being withdrawn from the market due to safety concerns.Ukoniq is a kinase inhibitor that was approved in 2021 for the treatment of adult patients...
by TractManager | Jun 1, 2022 | Health Technology Assessment
Focus of the Report: This Health Technology Assessment focuses on the use of functional electrical stimulation (FES) for treatment of foot drop in patients who have a history of stroke < 1 year prior to FES treatment. A mean 1-year threshold was implemented to ensure...
Recent Comments